In a surveillance analysis of patients receiving curative intent treatment for CRC, Guardant Reveal predicted recurrence
with up to 91% sensitivity.¹*
Sensitivity improves up to 91% with surveillance monitoring.¹
Explore how Guardant Reveal maximizes sensitivity in breast cancer surveillance.²
CRC, colorectal cancer.
*Sensitivity was calculated based on samples collected before or at recurrence.
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.